Join our live webinar to hear from leading scientists about recommended initial formats for launching bispecific antibody campaigns and the rationale behind these choices. We will also explore the ...

Another recent entrant is Johnson & Johnson's Rybrevant (amivantamab), a bispecific antibody targeting c-Met and EGFR, which is currently approved for EGFR-mutated NSCLC only. Analysts have ...

Other candidates are also coming through development, including Ottimo Pharma's bifunctional antibody directed at PD-1 and VEGFR2, jankistomig, and OncoC4's PD-1xVEGF bispecific AI-08, which are ...